Navigation Links
BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma
Date:4/14/2009

WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM (OncoVEX Pivotal Trial in Melanoma) Phase 3 study with OncoVEX (GM-CSF) in previously treated patients with Stage III and Stage IV melanoma had initiated. The study has commenced recruiting patients in the U.S. with sites in the United Kingdom, Germany and Australia due to open later in the year. Further details on this study can be found at www.oncovexgmcsf.com and at www.clinicaltrials.gov.

Dr Robert Coffin, Founder and Chief Technology Officer of BioVex Inc said:

"The treatment options for patients with recurrent or metastatic melanoma are currently very limited, with no therapy being approved or recognized to be effective in the second line setting and beyond. Currently, there are also very few late stage or pivotal clinical studies available for patients who have failed first line therapy. The initiation of this study, following the highly encouraging data generated in Phase 2, is therefore a significant milestone on the path towards meeting this major unmet need, and towards the approval of OncoVEX (GM-CSF) in this first indication."

OPTiM Phase 3 Trial Design

The OPTiM trial is a multi-national, open label, randomized Phase 3 study designed to assess the efficacy and safety of treatment with OncoVEX (GM-CSF) as compared to subcutaneously administered GM-CSF in patients with unresectable stage III (b-c) and Stage IV (M1a-c) disease. Patients will have received at least one prior therapy for active disease which includes any type of therapy including investigational drugs. A total of 360 patients will be enrolled (240 to
'/>"/>

SOURCE BioVex Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioVex Raises $40 Million in First Close of Series F Financing
2. BioVex to Present at the UBS Global Life Sciences Conference
3. BioVex Closes Second Round of Series E Financing
4. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
5. BioVex Appoints Dr. Thaddeus Pullano as VP, Quality Assurance
6. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
7. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
8. GlaxoSmithKline Commences Tender Offer to Acquire Genelabs Technologies, Inc.
9. SenesTech, Inc. Commences Product Registration Process With Australian Government
10. Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients
11. Lilly Commences Cash Tender Offer for ImClone Systems at $70 Per Share

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)...RNewswire-FirstCall/ -- VIA Pharmaceuticals, Inc. ...on the development of compounds for the treatment ...ounced that it has completed the last patient visi...1. ,, The FDG-PET trial enrolled 52 patients a...ada including Massachusetts General Hospital, Moun...
(Date:12/3/2009)...PRNewswire-FirstCall/ -- Inverness Medical Innovat...ling individuals to take charge of their health at...health management, has declared a dividend of $3.0...Preferred Stock ( IMA-PB). The dividend will be pa...are equal to the quotient of (a) $3.00 divided by ...
(Date:12/2/2009)...PRNewswire-FirstCall/ -- Martek Biosciences Corpor...ends to release the results of its fourth quarter ...oximately 4:00 p.m. Eastern Time (ET). Following ... conference call to discuss these results with inv...call live via webcast by visiting Martek,s web sit...
(Date:12/2/2009)...PRNewswire/ -- Reportlinker.com announces that a n...logue: ,, Carbondioxide Incubators - A Global ....com/p0164368/Carbondioxide-Incubators---A-Global-... most critical equipment used in microbiology, gen...r providing a controlled environment to grow and s...
Breaking Biology Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Trial of VIA-2291 4Martek to Announce Fourth Quarter and Fiscal Year 2009 Results 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4
...orts the potential for QLT,s drug elution technolo...r pressure, VANCOUVER, May 12 /PRNewswire-FirstCa...today results from a proof of concept trial conduc...ivery, Inc., of its punctal plug,drug delivery tec...elution,technology was effective in controlling in...
... May 12 WaferGen Biosystems,Inc. (OTC Bulletin Bo...t,gene expression, genotyping, cell biology and st...Alnoor Shivji, President and Chief Executive,Offic...odman & Renshaw,Fifth Annual Global Healthcare Con...08, at the Le Meridien Beach Plaza Hotel in Monte ...
...f., May 9 Bionovo, Inc.,(Nasdaq: BNVI ) today an...uarter Results, The company did not report any re...evenues for the three months ended March 31, 2007 ...logy transfer agreement with United,Biotechnology ...inated the,agreement following notice of material ...
Other Biology Technology:QLT reports initial proof of concept data for punctal plug delivery technology 2QLT reports initial proof of concept data for punctal plug delivery technology 3QLT reports initial proof of concept data for punctal plug delivery technology 4WaferGen to Present at the Rodman and Renshaw Fifth Annual Global Healthcare Conference 2Bionovo Reports First Quarter 2008 Financial Results 2Bionovo Reports First Quarter 2008 Financial Results 3Bionovo Reports First Quarter 2008 Financial Results 4Bionovo Reports First Quarter 2008 Financial Results 5Bionovo Reports First Quarter 2008 Financial Results 6
(Date:12/2/2009)... PHILADELPHIA Cigarette smoking and alcohol consu...gly predicts the patient,s future risk of death, a...ew study show a similar effect among those who con...ost cancer survivors are counseled to quit smoking... percent continued to smoke even after their cance...
(Date:12/2/2009)..., PHILADELPHIA Exposure to secondhand smoke for ...y increase the risk of breast cancer, even in wome...e question of whether exposure to side-stream smok... is unresolved," said Peggy Reynolds, Ph.D., senio...ncer Center,s Berkeley office. "While no single ep...
(Date:12/2/2009)... Recalls of ground beef, peanut butter, and other ...nd concern about food safety. They also are quietl...uipment and fostering new food safety regulations....he current issue of Chemical & Engineering News ,...te Editor Jyllian Kemsley and Senior Correspondent...
Breaking Biology News(10 mins):Head and neck cancer survivors who use alcohol and cigarettes have increased death risk 2Exposure to secondhand cigarette smoke over a lifetime increased breast cancer risk later in life 2Mediterranean Diet May Help Prevent Depression 58895 1Mediterranean Diet May Help Prevent Depression 58895 2Mediterranean Diet May Help Prevent Depression 58895 3SAGE launches Genes 26amp 3B Cancer 58891 1SAGE launches Genes 26amp 3B Cancer 58891 2Fewer U S Schools Selling Less Nutritious Food and Beverages 58888 1Fewer U S Schools Selling Less Nutritious Food and Beverages 58888 2
...motherapy drugs to specific cancer cells without t...ay be possible thanks to a nanoscale drug delivery...Department of Energy,s Ames Laboratory. , Using ti... carry drugs inside living cells, Ames Laboratory ...o control whether or not the particle delivers its...
...om the University of Alberta, the Yerkes National ...e Emory Transplant Center has successfully transpl...ls into monkeys, a procedure the researchers say r... critical supply problem in clinical islet cell tr..., along with recent work at the University of Minn...
...ound probes built by researchers at Duke,s Pratt S...s of dogs. The engineers said their demonstration ...r view during human endoscopic surgeries in which ...cisions. , If the probes prove beneficial in human...nd safer endoscopic surgeries, said the Duke engin...
Other Biology News:Cellular scale drug delivery from the inside out 2Cellular scale drug delivery from the inside out 3Diabetes researchers pioneer islet cell xenotransplantation in primate studies 23D ultrasound device poised to advance minimally invasive surgery 23D ultrasound device poised to advance minimally invasive surgery 3
Chicken Anti-Nucleobindin 1 (NUCB1) Antibody, Unconjugated from CHEMICON
Anti-Presenilin-1, N-terminus Polyclonal Antibody, Unconjugated from CHEMICON
Goat Anti-Syne-1 (N-19) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Mouse Anti-Human Kallikrein 1 Monoclonal Antibody, Unconjugated, Clone 323803 from R&D Systems
Biology Products: